Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

PerkinElmer receives commercial approval from the Central Drugs Standard Control Organization, India for its SARS-CoV-2 real-time RT-PCR Assay

Topics
Perkinelmer

ANI Press Release  |  New Delhi [India]  

Tennis player James Blake
PerkinElmer

PerkinElmer, Inc, a global leader committed to innovating for a healthier world, today announced that India has received commercial approval by the Central Drugs Standard Control Organization (CDSCO) for the new coronavirus nucleic acid detection kit.

This test is intended to help meet the heightened needs for COVID-19 testing in India.

PerkinElmer's RT-PCR test received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It is also marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and is now available in over 30 countries worldwide.

"COVID-19 continues to have a significant impact in India and it is imperative that testing facilities have the kits on hand to identify cases without delay. Receiving CDSCO approval for our RT-PCR test will bolster the solutions available to testing facilities across India and help toward improving health outcomes," said Shripad Joshi, Director, India and South Asia,

"Early detection is crucial to help control the spread of COVID-19 in the world's second-largest population, and the commercial approval for this new kit strengthens India's testing capabilities in order to more effectively address this pandemic," said Serge Moubarak, Managing Director, India, South Asia & Emerging Markets, PerkinElmer.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, June 10 2020. 23:31 IST
RECOMMENDED FOR YOU

PerkinElmer receives commercial approval from the Central Drugs Standard Control Organization, India for its SARS-CoV-2 real-time RT-PCR Assay

New Delhi [India] June 10 (ANI/BusinessWire India): PerkinElmer, Inc, a global leader committed to innovating for a healthier world, today announced that PerkinElmer India has received commercial approval by the Central Drugs Standard Control Organization (CDSCO) for the PerkinElmer new coronavirus nucleic acid detection kit. PerkinElmer, Inc, a global leader committed to innovating for a healthier world, today announced that India has received commercial approval by the Central Drugs Standard Control Organization (CDSCO) for the new coronavirus nucleic acid detection kit.

This test is intended to help meet the heightened needs for COVID-19 testing in India.

PerkinElmer's RT-PCR test received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It is also marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and is now available in over 30 countries worldwide.

"COVID-19 continues to have a significant impact in India and it is imperative that testing facilities have the kits on hand to identify cases without delay. Receiving CDSCO approval for our RT-PCR test will bolster the solutions available to testing facilities across India and help toward improving health outcomes," said Shripad Joshi, Director, India and South Asia,

"Early detection is crucial to help control the spread of COVID-19 in the world's second-largest population, and the commercial approval for this new kit strengthens India's testing capabilities in order to more effectively address this pandemic," said Serge Moubarak, Managing Director, India, South Asia & Emerging Markets, PerkinElmer.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

PerkinElmer receives commercial approval from the Central Drugs Standard Control Organization, India for its SARS-CoV-2 real-time RT-PCR Assay

PerkinElmer, Inc, a global leader committed to innovating for a healthier world, today announced that India has received commercial approval by the Central Drugs Standard Control Organization (CDSCO) for the new coronavirus nucleic acid detection kit.

This test is intended to help meet the heightened needs for COVID-19 testing in India.

PerkinElmer's RT-PCR test received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). It is also marketed as an in vitro diagnostic (IVD) device by meeting the requirements of the European In Vitro Diagnostic Directive (IVDD) and is now available in over 30 countries worldwide.

"COVID-19 continues to have a significant impact in India and it is imperative that testing facilities have the kits on hand to identify cases without delay. Receiving CDSCO approval for our RT-PCR test will bolster the solutions available to testing facilities across India and help toward improving health outcomes," said Shripad Joshi, Director, India and South Asia,

"Early detection is crucial to help control the spread of COVID-19 in the world's second-largest population, and the commercial approval for this new kit strengthens India's testing capabilities in order to more effectively address this pandemic," said Serge Moubarak, Managing Director, India, South Asia & Emerging Markets, PerkinElmer.

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22